N-carbamimidoyl-2-phenylquinoline-4-carboxamide hydrochloride | 181048-45-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-carbamimidoyl-2-phenylquinoline-4-carboxamide hydrochloride
• 英文别名: 2-phenylquinoline-4-carbonylguanidine Hydrochloride；N-carbamimidoyl-2-phenylquinoline-4-carboxamide;hydrochloride
• CAS: 181048-45-3
• 化学式: C₁₇H₁₄N₄O*ClH
• 分子量: 326.785
• InChiKey: AMJLHOKKHVWCGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.74
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94.4
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-苯基-4-喹啉羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.5h， 生成 N-carbamimidoyl-2-phenylquinoline-4-carboxamide hydrochloride
  参考文献：
  名称：

  SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF

  摘要：

  这项发明属于药物化学领域。具体而言，该发明涉及一类新型的小分子，其具有喹啉（或类似）结构，可作为雄激素受体活性拮抗剂，并且可用作治疗癌症（例如去势抵抗性前列腺癌）和其他与雄激素受体活性和/或雄激素受体表达有关的疾病的治疗药物。

  公开号：

  US20210244721A1

文献信息

• Quinoline-4-carbonylguanidine derivatives, process for producing the
  申请人：Mitsui Toatsu Chemicals, Inc.

  公开号：US05627193A1

  公开（公告）日：1997-05-06

  The present invention relates to quinoline-4-carbonylguanidine derivative represented by formula (1) ##STR1## and pharmaceutically acceptable salt thereof, a process for producing the same, and a Na.sup.+ /H.sup.+ exchanger inhibitor containing the compound as an active ingredient. The compounds of the present invention are useful as an agent for treating or preventing various diseases by hyperfunction of the Na.sup.+ /H.sup.+ exchanger and as a diagnostic agent for these diseases.

  本发明涉及由式（1）表示的喹啉-4-羰基胍衍生物及其药学上可接受的盐，制备该衍生物的方法，以及含有该化合物作为活性成分的Na+/H+交换抑制剂。本发明的化合物可用作治疗或预防由Na+/H+交换器的高功能引起的各种疾病的药剂，并可用作这些疾病的诊断剂。
• Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68)
  作者：Rami Musharrafieh、Jiantao Zhang、Peter Tuohy、Naoya Kitamura、Shreya Sai Bellampalli、Yanmei Hu、Rajesh Khanna、Jun Wang

  DOI：10.1021/acs.jmedchem.9b00115

  日期：2019.4.25

  Enterovirus D68 (EV-D68) is an atypical nonpolio enterovirus that mainly infects the respiratory system of humans, leading to moderate-to-severe respiratory diseases. In rare cases, EV-D68 can spread to the central nervous system and cause paralysis in infected patients, especially young children and immunocompromised individuals. There is currently no approved vaccine or antiviral available for the prevention and treatment of EV-D68. In this study, we aimed to improve the antiviral potency and selectivity of a previously reported EV-D68 inhibitor, dibucaine, through structure activity relationship studies. In total, 60 compounds were synthesized and tested against EV-D68 using the viral cytopathic effect assay. Three compounds 10a, 12a, and 12c were identified to have significantly improved potency (EC50 < 1 mu M) and a high selectivity index (>180) compared with dibucaine against five different strains of EV-D68 viruses. These compounds also showed potent antiviral activity in neuronal cells, such as A172 and SH-SY5Y cells, suggesting they might be further developed for the treatment of both respiratory infection as well as neuronal infection.
• Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0726254B1

  公开（公告）日：1998-05-06
• US5627193A
  申请人：——

  公开号：US5627193A

  公开（公告）日：1997-05-06
• SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US20210244721A1

  公开（公告）日：2021-08-12

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline (or similar) structure which function as antagonists of androgen receptor activity, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer) and other conditions characterized with androgen receptor activity and/or androgen receptor expression.

  这项发明属于药物化学领域。具体而言，该发明涉及一类新型的小分子，其具有喹啉（或类似）结构，可作为雄激素受体活性拮抗剂，并且可用作治疗癌症（例如去势抵抗性前列腺癌）和其他与雄激素受体活性和/或雄激素受体表达有关的疾病的治疗药物。